Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma

PURPOSE: Targeting tumor blood vessels is an attractive therapy in glioblastoma (GBM), but the mechanism of action of these agents and how they modulate delivery of concomitant chemotherapy are not clear in humans. We sought to elucidate how bevacizumab modulates tumor vasculature and the impact tho...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Gerstner, Elizabeth R., Emblem, Kyrre E., Chang, Ken, Vakulenko-Lagun, Bella, Yen, Yi-Fen, Beers, Andrew L., Dietrich, Jorg, Plotkin, Scott R., Catana, Ciprian, Hooker, Jacob M., Duda, Dan G., Rosen, Bruce, Kalpathy-Cramer, Jayashree, Jain, Rakesh K., Batchelor, Tracy
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7139851/
https://ncbi.nlm.nih.gov/pubmed/31558474
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1739
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky